Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
Status:
Terminated
Trial end date:
2005-11-03
Target enrollment:
Participant gender:
Summary
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to
identify the minimal effective dose of pentostatin defined as the lowest dose that produces a
response in 20% or more of patients while producing treatment failure (defines as death,
grade 3/4 toxicity, or progressive disease) in 40% or less of patients.